Drug class

Factor VII

Rather than an independent therapeutic drug class, "Factor VII" refers to a specific endogenous vitamin K–dependent clotting factor, typically administered as exogenous activated factor VII (factor VIIa) within the broader class of hemostatic agents and coagulation factors. Read more about Factor VII

5 drugs in this class 5 manufacturers

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs Anticoagulant-Induced Prothrombin DeficiencyTop indication · 34 prescription drugs

Showing 1–5 of 5 drugs

Sort

PROFILNINE (factor IX complex, prothrombin complex conc no.4, 3-factor)

FACTOR IX · HEMOPHILIA B

GRIFOLS

NOVOSEVEN RT (coagulation factor VIIa (recombinant))

FACTOR VII · BLEEDING EPISODE IN HEMOPHILIA A ·+6

NOVO NORDISK

SEVENFACT (coagulation factor VIIa recombinant-jncw)

FACTOR VII · BLEEDING EPISODE IN HEMOPHILIA A ·+1

LFB S.A DBA HEM

KCENTRA (human prothrombin complex concentrate 4-factor)

FACTOR IX · ANTICOAGULANT-INDUCED PROTHROMBIN DEFICIENCY

CSL Behring

BALFAXAR (human prothrombin complex concentrate-lans)

FACTOR IX · ANTICOAGULANT-INDUCED PROTHROMBIN DEFICIENCY

OCTAPHARMA USA

Filter & compare in the drug finder → Opens the drug finder with Factor VII preselected. Add indication or manufacturer filters there.

About Factor VII.

It promotes hemostasis by complexing with exposed tissue factor and directly activating factor X and factor IX on platelet surfaces, thereby generating a burst of thrombin that facilitates fibrin clot formation independently of factor VIII or factor IX.

Therapeutically, recombinant factor VIIa formulations serve as bypassing agents to manage and prevent bleeding episodes or surgical hemorrhage in patients with congenital hemophilia A or B with inhibitors, acquired hemophilia, congenital factor VII deficiency, and Glanzmann thrombasthenia.

fda.gov
Rather than an independent therapeutic drug class, "Factor VII" refers to a specific endogenous vitamin K–dependent clotting factor, typically administered as exogenous activated factor VII (factor VIIa) within the broader class of hemostatic agents and coagulation factors It promotes hemostasis by complexing with exposed tissue factor and directly activating factor X and factor IX on platelet surfaces, thereby generating a burst of thrombin that facilitates fibrin clot formation independently o...
nih.gov
Rather than an independent therapeutic drug class, "Factor VII" refers to a specific endogenous vitamin K–dependent clotting factor, typically administered as exogenous activated factor VII (factor VIIa) within the broader class of hemostatic agents and coagulation factors It promotes hemostasis by complexing with exposed tissue factor and directly activating factor X and factor IX on platelet surfaces, thereby generating a burst of thrombin that facilitates fibrin clot formation independently o...
fda.gov
Therapeutically, recombinant factor VIIa formulations serve as bypassing agents to manage and prevent bleeding episodes or surgical hemorrhage in patients with congenital hemophilia A or B with inhibitors, acquired hemophilia, congenital factor VII deficiency, and Glanzmann thrombasthenia
fda.gov
Therapeutically, recombinant factor VIIa formulations serve as bypassing agents to manage and prevent bleeding episodes or surgical hemorrhage in patients with congenital hemophilia A or B with inhibitors, acquired hemophilia, congenital factor VII deficiency, and Glanzmann thrombasthenia